



1641 #8
RECEIVED


JUN 19 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: A. Burchell et al. Examiner: Not Assigned
Serial No.: 09/972,105 Group Art Unit: 1641
Filed: October 4, 2001 Docket: 350013-76
Due Date: N/A Date Mailed: June 5, 2002
Title: PRENATAL DIAGNOSTIC METHODS

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on June 5, 2002.

By: 
Name: Joy Johnson

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner
for Patents
Washington, DC 20231

Dear Sir:

This document is a Supplemental Information Disclosure Statement to the above-cited patent application.

Attached hereto is at least one Form PTO-1449 listing documents believed relevant to the subject application. The submission of the following information is not intended, nor should it be construed, to constitute an admission that any patent, article, or other information referred to herein is "prior art" unless specifically designated as such. In accordance with 37 C.F.R. § 1.97(b) the filing of this information shall not be construed to mean that a search has been made or that no other material information may exist. Neither should its submission be construed to indicate that a thorough search should not be conducted by the Examiner.

It is believed that this disclosure complies with the requirements of 37 C.F.R. § 1.56, § 1.97, and § 1.98 and the Manual of Patent Examining Procedures § 707.05(b). If for some reason the Examiner considers otherwise, it is respectfully requested that the undersigned be telephoned so that any deficiencies can be remedied.

This Supplemental Information Disclosure Statement is being submitted before the mailing of an Office Action on the merits for the above-identified patent application. Therefore, no fee is due for submission of this Information Disclosure Statement, pursuant to 37 C.F.R. § 1.97(b)(3). Should an Office Action on the merits in fact have been mailed prior to the submission of this Supplemental Information Disclosure Statement, the undersigned hereby states that no item of information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Supplemental Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement. This is the required statement under 37 C.F.R. § 1.97(e), and no fee is therefore due under 37 C.F.R. § 1.97(d).

A copy of each document is enclosed. Some of the documents may have markings thereon. No significance is meant to be attached to the markings. These documents are not necessarily analogous art. Additionally, the order of the following documents is to be accorded no particular import as the order thereof is completely fortuitous.


It is respectfully requested that these documents be: (1) fully considered by the Patent and Trademark Office during the examination of this application; and (2) represented on any patent which may issue on the application. Applicants respectfully request that copies of the PTO-1449 forms, as considered and initialed by the Examiner, be returned with the next communication.

USSN 09/972,105

Docket No. 350013-76

British Patent Application GB 2313377A by Hirose et al. (Sumitomo Chemical Company Ltd.).

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Michael B. Farber", written over a horizontal line.

Dated: June 5, 2002

Michael B. Farber
Registration No. 32,612

OPPENHEIMER WOLFF & DONNELLY LLP
2029 Century Park East, 38th Floor
Los Angeles, California 90067-3024
(310) 788-5104
Fax (310) 788-5100